GLI1 and plasma cell myeloma: In myeloma, excessive ADAR1 activity leads to the R701G mutation through RNA editing of Glioma-associated oncogene 1 (GLI1) transcription, affecting cancer cell proliferation and resistance to anticancer drugs [123].